Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:18:29 EDT Sat 05 Oct 2024
Enter Symbol
or Name
USA
CA



Q:VERA - VERA THERAPEUTICS INC. - http://www.moscom.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VERA - Q0.137.35·41.955.040.84+0.350.9456.818,3285,11040.93  41.53  39.9250.69  9.2416:02:0516:0515 min RT 2¢

Recent Trades - Last 10 of 5110
Time ETExPriceChangeVolume
16:02:05Q40.840.35146
16:01:58Q40.840.35638
16:01:37Q40.840.352,082
16:01:14Q40.840.35348
16:01:08Q40.840.35343
16:00:06Q40.840.3514
16:00:05Q40.840.3548
16:00:05Q40.840.351,518
16:00:05Q40.840.35228
16:00:01Q40.840.3562

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-10-04 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-02 06:30U:VERANews ReleaseVera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
2024-10-02 06:30U:VERANews ReleaseVera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
2024-09-16 08:00U:VERANews ReleaseVera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
2024-09-12 08:00U:VERANews ReleaseVera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
2024-09-10 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-29 08:00U:VERANews ReleaseVera Therapeutics to Participate at September Investor Conferences
2024-08-09 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-08 08:00U:VERANews ReleaseVera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
2024-07-05 16:30U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-01 08:00U:VERANews ReleaseVera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
2024-06-11 16:01U:VERANews ReleaseVera Therapeutics Appoints Christy J. Oliger to Board of Directors
2024-06-07 16:05U:VERANews ReleaseVera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-06-07 16:05U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-28 08:00U:VERANews ReleaseVera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
2024-05-25 09:40U:VERANews ReleaseVera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
2024-05-09 08:00U:VERANews ReleaseVera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
2024-05-07 16:38U:VERANews ReleaseVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-02 08:00U:VERANews ReleaseVera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
2024-03-20 07:30U:VERANews ReleaseVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results